Adjusted Aggregate Production Quotas for Difenoxin, Diphenoxylate (for Conversion), and Marijuana, 34693-34695 [2015-14910]
Download as PDF
<![CDATA[
34693
Federal Register / Vol. 80, No. 116 / Wednesday, June 17, 2015 / Notices
management strategies for Fire Island
National Seashore for the next 15 to 20
years to support the protection of
important natural resources and
processes; significant recreation
resources; cultural resources of national,
state, and local significance; and
residential communities.
The park is composed of two distinct
units—the barrier island that runs
parallel to the south shore of Long
Island and the 613-acre William Floyd
Estate situated on the south shore of
Long Island near the east end of Fire
Island. To address the specific needs of
these two distinct units, the Draft GMP/
EIS includes two sets of alternatives.
One addresses park-wide alternatives
for Fire Island National Seashore with a
primary emphasis on the barrier island
and includes a no-action alternative and
two action alternatives. The other set of
alternatives focuses specifically on the
William Floyd Estate and includes a noaction and a single action alternative.
The Draft GMP/EIS also incorporates
plans for the Otis Pike High Dunes Fire
Island Wilderness and includes a draft
Wilderness Stewardship Plan for public
review concurrent with the Draft GMP/
EIS.
FOR FURTHER INFORMATION CONTACT:
Ellen Carlson, NPS/Northeast Region, 15
State Street, Boston, MA 02019. Phone:
(617) 223–5048. Email: Fire_Island_
GMP@nps.gov.
Dated: June 1, 2015.
Michael A. Caldwell,
Regional Director, Northeast Region, National
Park Service.
[FR Doc. 2015–14927 Filed 6–16–15; 8:45 am]
BILLING CODE 4310–WV–P
continuation or recurrence of material
injury to an industry in the United
States within a reasonably foreseeable
time.
Background
The Commission, pursuant to section
751(c) of the Tariff Act of 1930 (19
U.S.C. 1675(c)), instituted these reviews
on April 1, 2014 (79 FR 18311) and
determined on July 7, 2014 that it would
conduct full reviews (79 FR 42049, July
18, 2014). Notice of the scheduling of
the Commission’s reviews and of a
public hearing to be held in connection
therewith was given by posting copies
of the notice in the Office of the
Secretary, U.S. International Trade
Commission, Washington, DC, and by
publishing the notice in the Federal
Register on November 14, 2014 (79 FR
68299). The hearing was held in
Washington, DC, on March 26, 2015,
and all persons who requested the
opportunity were permitted to appear in
person or by counsel.
The Commission made these
determinations pursuant to section
751(c) of the Tariff Act of 1930 (19
U.S.C. 1675(c)). It completed and filed
its determinations in these reviews on
June 11, 2015. The views of the
Commission are contained in USITC
Publication 4538 (June 2015), entitled
Citric Acid and Certain Citrate Salts
from Canada and China: Investigation
Nos. 701–TA–456 and 731–TA–1151–
1152 (Review).
By order of the Commission.
Issued: June 12, 2015.
Lisa R. Barton,
Secretary to the Commission.
[FR Doc. 2015–14863 Filed 6–16–15; 8:45 am]
BILLING CODE 7020–02–P
INTERNATIONAL TRADE
COMMISSION
DEPARTMENT OF JUSTICE
[Investigation Nos. 701–TA–456 and 731–
TA–1151–1152 (Review)]
Drug Enforcement Administration
asabaliauskas on DSK5VPTVN1PROD with NOTICES
Citric Acid and Certain Citrate Salts
From Canada and China
[Docket No. DEA–392]
Determination
On the basis of the record 1 developed
in the subject five-year reviews, the
United States International Trade
Commission (‘‘Commission’’)
determines, pursuant to the Tariff Act of
1930, that revocation of the
countervailing duty order on citric acid
and certain citrate salts from China and
the antidumping duty orders on citric
acid and certain citrate salts from China
and Canada would be likely to lead to
1 The
record is defined in sec. 207.2(f) of the
Commission’s Rules of Practice and Procedure (19
CFR 207.2(f)).
VerDate Sep<11>2014
18:47 Jun 16, 2015
Jkt 235001
Manufacturer of Controlled
Substances Registration: Siemens
Healthcare Diagnostics, Inc.
ACTION:
Notice of registration.
PO 00000
Frm 00088
Fmt 4703
Sfmt 4703
Controlled substance
Tetrahydrocannabinols (7370) .....
Ecgonine (9180) ...........................
Morphine (9300) ...........................
Thebaine (9333) ...........................
Schedule
I
II
II
II
The company plans to produce the
listed controlled substances in bulk to
be used in the manufacture of reagents
and drug calibrator controls which are
DEA exempt products.
In reference to drug code 7370 the
company plans to bulk manufacture a
synthetic tetrahydrocannabinol. No
other activity for this drug code is
authorized for this registration.
Dated: June 11, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015–14912 Filed 6–16–15; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Siemens Healthcare
Diagnostics, Inc. applied to be registered
as a manufacturer of certain basic
classes of controlled substances. The
Drug Enforcement Administration
(DEA) grants Siemens Healthcare
Diagnostics, Inc. registration as a
manufacturer of those controlled
substances.
SUPPLEMENTARY INFORMATION: By notice
dated January 9, 2015, and published in
SUMMARY:
the Federal Register on January 26,
2015, 80 FR 3982, Siemens Healthcare
Diagnostics, Inc., Attn: RA, 100 GBC
Drive, Mailstop 514, Newark, Delaware
19702 applied to be registered as a
manufacturer of certain basic classes of
controlled substances. No comments or
objections were submitted to this notice.
The DEA has considered the factors in
21 U.S.C. 823(a) and determined that
the registration of Siemens Healthcare
Diagnostics, Inc. to manufacture the
basic classes of controlled substances is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971. The
DEA investigated the company’s
maintenance of effective controls
against diversion by inspecting and
testing the company’s physical security
systems, verifying the company’s
compliance with state and local laws,
and reviewing the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above-named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed:
Drug Enforcement Administration
[Docket No. DEA–411F]
Adjusted Aggregate Production
Quotas for Difenoxin, Diphenoxylate
(for Conversion), and Marijuana
Drug Enforcement
Administration, Department of Justice.
ACTION: Final order.
AGENCY:
E:\FR\FM\17JNN1.SGM
17JNN1
34694
Federal Register / Vol. 80, No. 116 / Wednesday, June 17, 2015 / Notices
This final order establishes
the adjusted 2015 aggregate production
quotas for difenoxin, diphenoxylate (for
conversion), and marijuana.
DATES: This order is effective June 17,
2015.
SUMMARY:
John
R. Scherbenske, Office of Diversion
Control, Drug Enforcement
Administration, 8701 Morrissette Drive,
Springfield, Virginia 22152, Telephone:
(202) 598–6812.
SUPPLEMENTARY INFORMATION:
FOR FURTHER INFORMATION CONTACT:
Legal Authority
The DEA implements and enforces
titles II and III of the Comprehensive
Drug Abuse Prevention and Control Act
of 1970, as amended. 21 U.S.C. 801–971.
Titles II and III are referred to as the
‘‘Controlled Substances Act’’ and the
‘‘Controlled Substances Import and
Export Act,’’ respectively, and are
collectively referred to as the
‘‘Controlled Substances Act’’ or the
‘‘CSA’’ for the purposes of this action.
The DEA publishes the implementing
regulations for these statutes in title 21
of the Code of Federal Regulations
(CFR), Chapter II. The CSA and its
implementing regulations are designed
to prevent, detect, and eliminate the
diversion of controlled substances and
listed chemicals into the illicit market
while providing for the legitimate
medical, scientific, research, and
industrial needs of the United States.
Controlled substances have the potential
for abuse and dependence and are
controlled to protect the public health
and safety.
Section 306 of the Controlled
Substances Act (CSA) (21 U.S.C. 826)
requires the Attorney General to
establish aggregate production quotas
for each basic class of controlled
substance listed in schedules I and II
each year. The Attorney General has
delegated this function to the
Administrator of the DEA, 28 CFR
0.100.
Background
The DEA established the initial 2015
aggregate production quotas and
assessments for annual need on
September 8, 2014 (79 FR 53216). That
notice stipulated that, as provided for in
21 CFR 1303.13 and 21 CFR 1315.13, all
aggregate production quotas and
assessments of annual need are subject
to adjustment. Based on unanticipated
medical, scientific, research, and
industrial needs of the United States,
the DEA proposed to adjust the
established 2015 aggregate production
quotas for the schedule I and II
controlled substances difenoxin,
diphenoxylate (for conversion), and
marijuana to be manufactured in the
United States in 2015. The notice of
proposed adjustment was published in
the Federal Register on Wednesday,
April 8, 2015 (80 FR 18867). All
interested persons were invited to
comment on or object to the proposed
adjusted aggregate production quotas on
or before May 8, 2015.
Comments Received
Two companies, one institution of
higher education, and five private
citizens submitted timely comments in
response to the proposed adjustment of
these three controlled substances. The
comments from the institution of higher
education and one of the private
citizens were in support of the proposed
increases for these three controlled
substances. The two companies and one
private citizen supported the proposed
adjustment and requested further
increases to the APQs to support
research, additional product
development efforts, and increases in
manufacturing demands. Further
comments received from three private
citizens were outside the scope of the
proposed APQ notice. The DEA
appreciates the support for this adjusted
2015 aggregate production quota for
difenoxin, diphenoxylate (for
conversion), and marijuana, which is
intended to provide for the estimated
scientific, research, and industrial needs
of the United States.
Determination for Adjusting the
Aggregate Production Quotas for
Difenoxin, Diphenoxylate (for
Conversion), and Marijuana
In accordance with 21 CFR 1303.13,
the DEA has taken into consideration
the above comments along with the
relevant 2014 year-end inventories,
initial 2015 manufacturing quotas, 2015
export requirements, actual and
projected 2015 sales, research and
product development requirements, and
information derived from additional
applications for manufacturing quota
received since the April 8, 2015
publication of the notice of proposed
adjustments to the aggregate production
quotas for difenoxin, diphenoxylate (for
conversion), and marijuana. Upon
consideration of the above, the Acting
Administrator has determined to
increase the 2015 aggregate production
quotas for difenoxin and marijuana
beyond that which was previously
proposed. Regarding the aggregate
production quota for diphenoxylate (for
conversion), the Acting Administrator
has determined that the proposed
aggregate production quota adjustment
for this substance is sufficient to meet
the current 2015 estimated medical,
scientific, research, and industrial needs
of the United States and to provide for
adequate reserve stock.
Pursuant to the above, the Acting
Administrator hereby establishes the
2015 aggregate production quotas for
difenoxin, diphenoxylate (for
conversion), and marijuana, expressed
in grams of anhydrous acid or base, as
follows:
Previously
established
2015 quota
(g)
Basic class—schedule I
asabaliauskas on DSK5VPTVN1PROD with NOTICES
Difenoxin ..................................................................................................................................................................
Marijuana .................................................................................................................................................................
Diphenoxylate (for conversion) ................................................................................................................................
18:47 Jun 16, 2015
Jkt 235001
PO 00000
Frm 00089
Fmt 4703
50
125,000
Previously
established
2015 quota
(g)
Basic class—schedule II
VerDate Sep<11>2014
Adjusted
2015 quota
(g)
Sfmt 4703
E:\FR\FM\17JNN1.SGM
17JNN1
11,000
658,000
Adjusted
2015 quota
(g)
0
75,000
34695
Federal Register / Vol. 80, No. 116 / Wednesday, June 17, 2015 / Notices
Dated: June 11, 2015.
Chuck Rosenberg,
Acting Administrator.
Background
[FR Doc. 2015–14910 Filed 6–16–15; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–410F]
Controlled Substances: 2015
Established Aggregate Production
Quotas for Three Temporarily
Controlled Synthetic Cannabinoids
Drug Enforcement
Administration, Department of Justice.
ACTION: Final order.
AGENCY:
This final order establishes
the initial 2015 aggregate production
quotas for three temporarily controlled
synthetic cannabinoids: N-(1-amino-3methyl-1-oxobutan-2-yl)-1(cyclohexylmethyl)-1H-indazole-3carboxamide (AB-CHMINACA), N-(1amino-3-methyl-1-oxobutan-2-yl)-1pentyl-1H-indazole-3-carboxamide (ABPINACA), and [1-(5-fluoropentyl)-1Hindazol-3-yl](naphthalen-1yl)methanone (THJ-2201).
DATES: Effective June 17, 2015.
FOR FURTHER INFORMATION CONTACT: John
R. Scherbenske, Office of Diversion
Control, Drug Enforcement
Administration; Mailing Address: 8701
Morrissette Drive, Springfield, Virginia
22152; Telephone: (202) 598–6812.
SUPPLEMENTARY INFORMATION:
SUMMARY:
Section 306 of the Controlled
Substances Act (CSA) (21 U.S.C. 826)
requires the Attorney General to
establish aggregate production quotas
for each basic class of controlled
substance listed in schedules I and II
and for ephedrine, pseudoephedrine,
and phenylpropanolamine. The
Attorney General has delegated this
authority to the Administrator of the
DEA. 28 CFR 0.100(b).
On January 30, 2015, the DEA
published in the Federal Register a final
order to temporarily place three
synthetic cannabinoids, N-(1-amino-3methyl-1-oxobutan-2-yl)-1(cyclohexylmethyl)-1H-indazole-3carboxamide (AB-CHMINACA), N-(1amino-3-methyl-1-oxobutan-2-yl)-1pentyl-1H-indazole-3-carboxamide (ABPINACA), and [1-(5-fluoropentyl)-1Hindazol-3-yl](naphthalen-1yl)methanone (THJ-2201), into schedule
I of the CSA (80 FR 5042), making all
regulatory controls pertaining to
schedule I controlled substances
applicable to AB-CHMINACA, ABPINACA, and THJ-2201, including the
requirement to obtain a manufacturing
quota pursuant to 21 CFR part 1303.
The 2015 aggregate production quotas
for AB-CHMINACA, AB-PINACA, and
THJ-2201 represent those quantities that
may be manufactured in the United
States in 2015 to provide for the
estimated scientific, research, and
industrial needs of the United States,
lawful export requirements, and the
establishment and maintenance of
reserve stocks.
On March 20, 2015, the DEA
published a notice titled, ‘‘Controlled
Substances: 2015 Proposed Aggregate
Production Quotas for Three
Temporarily Controlled Synthetic
Cannabinoids’’ in the Federal Register
(80 FR 15034). That notice proposed the
2015 aggregate production quotas for
AB-CHMINACA, AB-PINACA, and THJ2201. Interested persons were invited to
comment on or object to the proposed
aggregate production quotas for ABCHMINACA, AB-PINACA, and THJ2201 on or before April 20, 2015. No
comments were received.
Analysis for 2015 Established Aggregate
Production Quotas
In determining the 2015 aggregate
production quotas for N-(1-amino-3methyl-1-oxobutan-2-yl)-1(cyclohexylmethyl)-1H-indazole-3carboxamide (AB-CHMINACA), N-(1amino-3-methyl-1-oxobutan-2-yl)-1pentyl-1H-indazole-3-carboxamide (ABPINACA), and [1-(5-fluoropentyl)-1Hindazol-3-yl](naphthalen-1yl)methanone (THJ-2201), the DEA has
taken into consideration the factors set
forth at 21 CFR 1303.11, pursuant to 21
U.S.C. 826(a), and other relevant factors,
including 2015 export requirements,
industrial use, applications for quotas,
as well as information on research and
product development requirements.
Pursuant to 21 U.S.C. 826 and in
accordance with 21 CFR 1303.11, the
Acting Administrator hereby establishes
the 2015 aggregate production quotas for
AB-CHMINACA, AB-PINACA, and THJ2201, expressed in grams of anhydrous
acid or base, as follows:
Established
2015 quota
(g)
Basic class—schedule I
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA) .................................
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) ..........................................................
[1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone (THJ-2201) ..................................................................................
asabaliauskas on DSK5VPTVN1PROD with NOTICES
In accordance with 21 CFR 1303.13,
upon consideration of the relevant
factors, the Acting Administrator may
adjust the 2015 aggregate production
quotas for AB-CHMINACA, ABPINACA, and THJ-2201 as needed.
Dated: June 11, 2015.
Chuck Rosenberg,
Acting Administrator.
[FR Doc. 2015–14909 Filed 6–16–15; 8:45 am]
BILLING CODE 4410–09–P
VerDate Sep<11>2014
18:47 Jun 16, 2015
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Registration: Mylan Technologies, Inc.
ACTION:
Jkt 235001
Notice of registration.
Mylan Technologies, Inc.
applied to be registered as an importer
of certain basic classes of controlled
substances. The Drug Enforcement
Administration (DEA) grants Mylan
Technologies, Inc. registration as an
importer of those controlled substances.
SUMMARY:
PO 00000
Frm 00090
Fmt 4703
Sfmt 4703
By notice
dated February 11, 2015, and published
in the Federal Register on February 19,
2015, 80 FR 8902, Mylan Technologies,
Inc., 110 Lake Street, Saint Albans,
Vermont 05478 applied to be registered
as an importer of certain basic classes of
controlled substances. No comments or
objections were submitted for this
notice.
The DEA has considered the factors in
21 U.S.C. 823, 952(a) and 958(a) and
determined that the registration of
Mylan Technologies, Inc. to import the
basic classes of controlled substances is
consistent with the public interest and
with United States obligations under
SUPPLEMENTARY INFORMATION:
DEPARTMENT OF JUSTICE
15
15
15
E:\FR\FM\17JNN1.SGM
17JNN1
]]>Agencies
[Federal Register Volume 80, Number 116 (Wednesday, June 17, 2015)]
[Notices]
[Pages 34693-34695]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-14910]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-411F]
Adjusted Aggregate Production Quotas for Difenoxin, Diphenoxylate
(for Conversion), and Marijuana
AGENCY: Drug Enforcement Administration, Department of Justice.
ACTION: Final order.
-----------------------------------------------------------------------
[[Page 34694]]
SUMMARY: This final order establishes the adjusted 2015 aggregate
production quotas for difenoxin, diphenoxylate (for conversion), and
marijuana.
DATES: This order is effective June 17, 2015.
FOR FURTHER INFORMATION CONTACT: John R. Scherbenske, Office of
Diversion Control, Drug Enforcement Administration, 8701 Morrissette
Drive, Springfield, Virginia 22152, Telephone: (202) 598-6812.
SUPPLEMENTARY INFORMATION:
Legal Authority
The DEA implements and enforces titles II and III of the
Comprehensive Drug Abuse Prevention and Control Act of 1970, as
amended. 21 U.S.C. 801-971. Titles II and III are referred to as the
``Controlled Substances Act'' and the ``Controlled Substances Import
and Export Act,'' respectively, and are collectively referred to as the
``Controlled Substances Act'' or the ``CSA'' for the purposes of this
action. The DEA publishes the implementing regulations for these
statutes in title 21 of the Code of Federal Regulations (CFR), Chapter
II. The CSA and its implementing regulations are designed to prevent,
detect, and eliminate the diversion of controlled substances and listed
chemicals into the illicit market while providing for the legitimate
medical, scientific, research, and industrial needs of the United
States. Controlled substances have the potential for abuse and
dependence and are controlled to protect the public health and safety.
Section 306 of the Controlled Substances Act (CSA) (21 U.S.C. 826)
requires the Attorney General to establish aggregate production quotas
for each basic class of controlled substance listed in schedules I and
II each year. The Attorney General has delegated this function to the
Administrator of the DEA, 28 CFR 0.100.
Background
The DEA established the initial 2015 aggregate production quotas
and assessments for annual need on September 8, 2014 (79 FR 53216).
That notice stipulated that, as provided for in 21 CFR 1303.13 and 21
CFR 1315.13, all aggregate production quotas and assessments of annual
need are subject to adjustment. Based on unanticipated medical,
scientific, research, and industrial needs of the United States, the
DEA proposed to adjust the established 2015 aggregate production quotas
for the schedule I and II controlled substances difenoxin,
diphenoxylate (for conversion), and marijuana to be manufactured in the
United States in 2015. The notice of proposed adjustment was published
in the Federal Register on Wednesday, April 8, 2015 (80 FR 18867). All
interested persons were invited to comment on or object to the proposed
adjusted aggregate production quotas on or before May 8, 2015.
Comments Received
Two companies, one institution of higher education, and five
private citizens submitted timely comments in response to the proposed
adjustment of these three controlled substances. The comments from the
institution of higher education and one of the private citizens were in
support of the proposed increases for these three controlled
substances. The two companies and one private citizen supported the
proposed adjustment and requested further increases to the APQs to
support research, additional product development efforts, and increases
in manufacturing demands. Further comments received from three private
citizens were outside the scope of the proposed APQ notice. The DEA
appreciates the support for this adjusted 2015 aggregate production
quota for difenoxin, diphenoxylate (for conversion), and marijuana,
which is intended to provide for the estimated scientific, research,
and industrial needs of the United States.
Determination for Adjusting the Aggregate Production Quotas for
Difenoxin, Diphenoxylate (for Conversion), and Marijuana
In accordance with 21 CFR 1303.13, the DEA has taken into
consideration the above comments along with the relevant 2014 year-end
inventories, initial 2015 manufacturing quotas, 2015 export
requirements, actual and projected 2015 sales, research and product
development requirements, and information derived from additional
applications for manufacturing quota received since the April 8, 2015
publication of the notice of proposed adjustments to the aggregate
production quotas for difenoxin, diphenoxylate (for conversion), and
marijuana. Upon consideration of the above, the Acting Administrator
has determined to increase the 2015 aggregate production quotas for
difenoxin and marijuana beyond that which was previously proposed.
Regarding the aggregate production quota for diphenoxylate (for
conversion), the Acting Administrator has determined that the proposed
aggregate production quota adjustment for this substance is sufficient
to meet the current 2015 estimated medical, scientific, research, and
industrial needs of the United States and to provide for adequate
reserve stock.
Pursuant to the above, the Acting Administrator hereby establishes
the 2015 aggregate production quotas for difenoxin, diphenoxylate (for
conversion), and marijuana, expressed in grams of anhydrous acid or
base, as follows:
------------------------------------------------------------------------
Previously
Basic class--schedule I established Adjusted 2015
2015 quota (g) quota (g)
------------------------------------------------------------------------
Difenoxin............................... 50 11,000
Marijuana............................... 125,000 658,000
------------------------------------------------------------------------
------------------------------------------------------------------------
Previously
Basic class--schedule II established Adjusted 2015
2015 quota (g) quota (g)
------------------------------------------------------------------------
Diphenoxylate (for conversion).......... 0 75,000
------------------------------------------------------------------------
[[Page 34695]]
Dated: June 11, 2015.
Chuck Rosenberg,
Acting Administrator.
[FR Doc. 2015-14910 Filed 6-16-15; 8:45 am]
BILLING CODE 4410-09-P
